October 8, 2020
The last 5 years has seen a step change in how the biopharmaceutical industry considers investments in enabling technologies for drug development. Companies involved in developing lifesaving medicines for patients have recognised that an on-premises stack of bespoke and/or highly customised applications requires a continual significant investment in technology and capabilities that are not core to the business of developing life-saving medicines...
